Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. ACPD - Wikipedia
ACPD - Wikipedia
From Wikipedia, the free encyclopedia
For other uses, see ACPD (disambiguation).
ACPD
Stereo, skeletal formula of ACPD ((1S,3S)-1-amino,-1,3-dicarboxylic acid)
Stereo, skeletal formula of ACPD ((1S,3S)-1-amino,-1,3-dicarboxylic acid)
Names
Preferred IUPAC name
1-Aminocyclopentane-1,3-dicarboxylic acid[1]
Identifiers
CAS Number
  • 39026-63-6 ☒N
  • 56827-69-1 (1R,3S) checkY
  • 111900-32-4 (1S,3R) checkY
3D model (JSmol)
  • Interactive image
Abbreviations ACPD
ChEMBL
  • ChEMBL168278 ☒N
ChemSpider
  • 1270 ☒N
  • 201559 (1R,3R) checkY
  • 66220 (1R,3S) checkY
  • 94574 (1S,3R) checkY
  • 5036967 (1S,3S) ☒N
MeSH 1-amino-1,3-dicarboxycyclopentane
PubChem CID
  • 1310
  • 44381972 (1S)
  • 231345 (1R,3R)
  • 73537 (1R,3S)
  • 104766 (1S,3R)
  • 6604704 (1S,3S)
RTECS number
  • GY4060000 (1S,3R)
CompTox Dashboard (EPA)
  • DTXSID701272273 Edit this at Wikidata
InChI
  • InChI=1S/C7H11NO4/c8-7(6(11)12)2-1-4(3-7)5(9)10/h4H,1-3,8H2,(H,9,10)(H,11,12) ☒N
    Key: YFYNOWXBIBKGHB-UHFFFAOYSA-N ☒N
SMILES
  • NC1(CCC(C1)C(O)=O)C(O)=O
Properties
Chemical formula
C7H11NO4
Molar mass 173.168 g·mol−1
Appearance White crystals
Solubility in water
20 g dm−3
Solubility in ethanol 240 mg dm−3
log P −0.709
Acidity (pKa) 2.112
Basicity (pKb) 11.885
Isoelectric point 2.84
Hazards
GHS labelling:
Pictograms
GHS07: Exclamation mark
Signal word
Warning
Hazard statements
H302, H312, H315, H319, H332, H335
Precautionary statements
P261, P280, P305+P351+P338
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references
Chemical compound

1-Amino-1,3-dicarboxycyclopentane (ACPD) is a chemical compound that binds to the metabotropic glutamate receptor (mGluR),[2] acting as a mGluR agonist. ACPD is a rigid analogue of the neurotransmitter glutamate and does not activate ionotropic glutamate receptors.[3] However, it has been reported to be an agonist of the glycine site of the NMDA receptor.[citation needed] ACPD can induce convulsions in neonatal rats.[4]

References

[edit]
  1. ^ "1-amino-1,3-dicarboxycyclopentane - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 25 March 2005. Identification and Related Records. Retrieved 15 October 2011.
  2. ^ Schoepp DD, True RA (September 1992). "1S,3R-ACPD-sensitive (metabotropic) [3H]glutamate receptor binding in membranes". Neurosci. Lett. 145 (1): 100–4. doi:10.1016/0304-3940(92)90213-Q. PMID 1461560. S2CID 34921347.
  3. ^ Manzoni O, Fagni L, Pin JP, Rassendren F, Poulat F, Sladeczek F, Bockaert J (July 1990). "(trans)-1-amino-cyclopentyl-1,3-dicarboxylate stimulates quisqualate phosphoinositide-coupled receptors but not ionotropic glutamate receptors in striatal neurons and Xenopus oocytes". Mol. Pharmacol. 38 (1): 1–6. PMID 2164627.
  4. ^ McDonald JW, Fix AS, Tizzano JP, Schoepp DD (October 1993). "Seizures and brain injury in neonatal rats induced by 1S,3R-ACPD, a metabotropic glutamate receptor agonist". J. Neurosci. 13 (10): 4445–55. doi:10.1523/JNEUROSCI.13-10-04445.1993. PMC 6576384. PMID 8410197.
Glutamate receptor modulators
  • v
  • t
  • e
Ionotropic glutamate receptor modulators
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
  • Agonists: Main site agonists: 5-Fluorowillardiine
  • Acromelic acid (acromelate)
  • AMPA
  • BOAA
  • Domoic acid
  • Glutamate
  • Ibotenic acid
  • Proline
  • Quisqualic acid
  • Willardiine; Positive allosteric modulators: Aniracetam
  • Cyclothiazide
  • CX-516
  • CX-546
  • CX-614
  • Farampator (CX-691, ORG-24448)
  • CX-717
  • CX-1739
  • CX-1942
  • Diazoxide
  • Hydrochlorothiazide (HCTZ)
  • IDRA-21
  • LY-392098
  • LY-395153
  • LY-404187
  • LY-451646
  • LY-503430
  • Mibampator (LY-451395)
  • Nooglutyl
  • ORG-26576
  • Oxiracetam
  • PEPA
  • Pesampator (BIIB-104, PF-04958242)
  • Piracetam
  • Pramiracetam
  • S-18986
  • Tulrampator (S-47445, CX-1632)
  • Antagonists: ACEA-1011
  • ATPO
  • Becampanel
  • Caroverine
  • CNQX
  • Dasolampanel
  • DNQX
  • Fanapanel (MPQX)
  • GAMS
  • Kaitocephalin
  • Kynurenic acid
  • Kynurenine
  • Licostinel (ACEA-1021)
  • NBQX
  • PNQX
  • Selurampanel
  • Tezampanel
  • Theanine
  • Topiramate
  • YM90K
  • Zonampanel; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
  • Cyclopropane
  • Enflurane
  • Ethanol (alcohol)
  • Evans blue
  • GYKI-52466
  • GYKI-53655
  • Halothane
  • Irampanel
  • Isoflurane
  • Perampanel
  • Pregnenolone sulfate
  • Sevoflurane
  • Talampanel; Unknown/unsorted antagonists: Minocycline
KARTooltip Kainate receptor
  • Agonists: Main site agonists: 5-Bromowillardiine
  • 5-Iodowillardiine
  • Acromelic acid (acromelate)
  • AMPA
  • ATPA
  • Domoic acid
  • Glutamate
  • Ibotenic acid
  • Kainic acid
  • LY-339434
  • Proline
  • Quisqualic acid
  • SYM-2081; Positive allosteric modulators: Cyclothiazide
  • Diazoxide
  • Enflurane
  • Halothane
  • Isoflurane
  • Antagonists: ACEA-1011
  • CNQX
  • Dasolampanel
  • DNQX
  • GAMS
  • Kaitocephalin
  • Kynurenic acid
  • Licostinel (ACEA-1021)
  • LY-382884
  • NBQX
  • NS102
  • Selurampanel
  • Tezampanel
  • Theanine
  • Topiramate
  • UBP-302; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
  • Enflurane
  • Ethanol (alcohol)
  • Evans blue
  • NS-3763
  • Pregnenolone sulfate
NMDARTooltip N-Methyl-D-aspartate receptor
  • Agonists: Main site agonists: AMAA
  • Aspartate
  • Glutamate
  • Homocysteic acid (L-HCA)
  • Homoquinolinic acid
  • Ibotenic acid
  • NMDA
  • Proline
  • Quinolinic acid
  • Tetrazolylglycine
  • Theanine; Glycine site agonists: β-Fluoro-D-alanine
  • ACBD
  • ACC (ACPC)
  • ACPD
  • AK-51
  • Apimostinel (NRX-1074)
  • B6B21
  • CCG
  • D-Alanine
  • D-Cycloserine
  • D-Serine
  • DHPG
  • Dimethylglycine
  • Glycine
  • HA-966
  • L-687,414
  • L-Alanine
  • L-Serine
  • Milacemide
  • Neboglamine (nebostinel)
  • Rapastinel (GLYX-13)
  • Sarcosine; Polyamine site agonists: Neomycin
  • Spermidine
  • Spermine; Other positive allosteric modulators: 24S-Hydroxycholesterol
  • DHEATooltip Dehydroepiandrosterone (prasterone)
  • DHEA sulfate (prasterone sulfate)
  • Epipregnanolone sulfate
  • Plazinemdor
  • Pregnenolone sulfate
  • SAGE-201
  • SAGE-301
  • SAGE-718
  • Antagonists: Competitive antagonists: AP5 (APV)
  • AP7
  • CGP-37849
  • CGP-39551
  • CGP-39653
  • CGP-40116
  • CGS-19755
  • CPP
  • Kaitocephalin
  • LY-233053
  • LY-235959
  • LY-274614
  • MDL-100453
  • Midafotel (d-CPPene)
  • NPC-12626
  • NPC-17742
  • PBPD
  • PEAQX
  • Perzinfotel
  • PPDA
  • SDZ-220581
  • Selfotel; Glycine site antagonists: 4-Cl-KYN (AV-101)
  • 5,7-DCKA
  • 7-CKA
  • ACC
  • ACEA-1011
  • ACEA-1328
  • Apimostinel (NRX-1074)
  • AV-101
  • Carisoprodol
  • CGP-39653
  • CNQX
  • D-Cycloserine
  • DNQX
  • Felbamate
  • Gavestinel
  • GV-196771
  • Harkoseride
  • Kynurenic acid
  • Kynurenine
  • L-689560
  • L-701324
  • Licostinel (ACEA-1021)
  • LU-73068
  • MDL-105519
  • Meprobamate
  • MRZ 2/576
  • PNQX
  • Rapastinel (GLYX-13)
  • ZD-9379; Polyamine site antagonists: Arcaine
  • Co 101676
  • Diaminopropane
  • Diethylenetriamine
  • Huperzine A
  • Putrescine; Uncompetitive pore blockers (mostly dizocilpine site): 2-MDP
  • 3-HO-PCP
  • 3-MeO-PCE
  • 3-MeO-PCMo
  • 3-MeO-PCP
  • 4-MeO-PCP
  • 8A-PDHQ
  • 18-MC
  • α-Endopsychosin
  • Alaproclate
  • Alazocine (SKF-10047)
  • Amantadine
  • Aptiganel
  • Argiotoxin-636
  • Arketamine
  • ARL-12495
  • ARL-15896-AR
  • ARL-16247
  • Budipine
  • CNS-5161
  • Coronaridine
  • Delucemine (NPS-1506)
  • Dexoxadrol
  • Dextrallorphan
  • Dextromethadone
  • Dextromethorphan
  • Dextrorphan
  • Dieticyclidine
  • Diphenidine
  • Dizocilpine
  • Ephenidine
  • Esketamine
  • Etoxadrol
  • Eticyclidine
  • F-17475
  • Fluorolintane
  • Gacyclidine
  • Ibogaine
  • Ibogamine
  • Indantadol
  • Ketamine
  • Ketobemidone
  • Lanicemine
  • Levomethadone
  • Levomethorphan
  • Levomilnacipran
  • Levorphanol
  • Loperamide
  • Memantine
  • Methadone
  • Methorphan
  • Methoxetamine
  • Methoxphenidine
  • Milnacipran
  • Morphanol
  • NEFA
  • Neramexane
  • Nitromemantine
  • Noribogaine
  • Norketamine
  • Orphenadrine
  • PCPr
  • PD-137889
  • Pethidine (meperidine)
  • Phencyclamine
  • Phencyclidine
  • Propoxyphene
  • Remacemide
  • Rhynchophylline
  • Rimantadine
  • Rolicyclidine
  • Sabeluzole
  • Tabernanthine
  • Tenocyclidine
  • Tiletamine
  • Tramadol; Ifenprodil (NR2B) site antagonists:
  • Besonprodil
  • Buphenine (nylidrin)
  • CO-101244 (PD-174494)
  • Eliprodil
  • Haloperidol
  • Isoxsuprine
  • Radiprodil (RGH-896)
  • Rislenemdaz (CERC-301, MK-0657)
  • Ro 8-4304
  • Ro 25-6981
  • Safaprodil
  • Traxoprodil (CP-101606); NR2A-selective antagonists: MPX-004
  • MPX-007
  • TCN-201
  • TCN-213; Cations: Hydrogen
  • Magnesium
  • Zinc; Alcohols/volatile anesthetics/related: Benzene
  • Butane
  • Chloroform
  • Cyclopropane
  • Desflurane
  • Diethyl ether
  • Enflurane
  • Ethanol (alcohol)
  • Halothane
  • Hexanol
  • Isoflurane
  • Methoxyflurane
  • Nitrous oxide
  • Octanol
  • Sevoflurane
  • Toluene
  • Trichloroethane
  • Trichloroethanol
  • Trichloroethylene
  • Urethane
  • Xenon
  • Xylene; Unknown/unsorted antagonists: ARR-15896
  • Bumetanide
  • Caroverine
  • Conantokin
  • D-αAA
  • Dexanabinol
  • Flufenamic acid
  • Flupirtine
  • FPL-12495
  • FR-115427
  • Furosemide
  • Hodgkinsine
  • Ipenoxazone (MLV-6976)
  • MDL-27266
  • Metaphit
  • Minocycline
  • MPEP
  • Niflumic acid
  • Pentamidine
  • Pentamidine isethionate
  • Piretanide
  • Psychotridine
  • Transcrocetin (saffron)
  • Unsorted: Allosteric modulators: AGN-241751
  • See also: Receptor/signaling modulators
  • Metabotropic glutamate receptor modulators
  • Glutamate metabolism/transport modulators
  • v
  • t
  • e
Metabotropic glutamate receptor modulators
Group I
mGluR1Tooltip Metabotropic glutamate receptor 1
  • Agonists: ACPD
  • DHPG
  • Glutamate
  • Ibotenic acid
  • Quisqualic acid
  • Ro01-6128
  • Ro67-4853
  • Ro67-7476
  • VU-71
  • Theanine
  • Antagonists: BAY 36-7620
  • CPCCOEt
  • Cyclothiazide
  • LY-367,385
  • LY-456,236
  • MCPG
  • NPS-2390
mGluR5Tooltip Metabotropic glutamate receptor 5
  • Agonists: ACPD
  • ADX-47273
  • CDPPB
  • CHPG
  • DFB
  • DHPG
  • Glutamate
  • Ibotenic acid
  • Quisqualic acid
  • VU-1545; Positive allosteric modulators: LSN2463359
  • Antagonists: CTEP
  • DMeOB
  • LY-344,545
  • Mavoglurant
  • MCPG
  • NPS-2390
  • Remeglurant
  • SIB-1757
  • SIB-1893; Negative allosteric modulators: AZD9272
  • Basimglurant
  • Dipraglurant
  • Fenobam
  • GRN-529
  • MPEP
  • MTEP
  • Raseglurant
Group II
mGluR2Tooltip Metabotropic glutamate receptor 2
  • Agonists: BINA
  • CBiPES
  • DCG-IV
  • Eglumetad (LY-354740)
  • Glutamate
  • Ibotenic acid
  • LY-379,268
  • LY-487,379
  • LY-566,332
  • MGS-0028
  • Pomaglumetad (LY-404039)
  • Pomaglumetad methionil (LY-2140023)
  • Talaglumetad (LY-544344); Positive allosteric modulators: JNJ-40411813 (ADX-71149)
  • Antagonists: APICA
  • CECXG
  • EGLU
  • HYDIA
  • LY-307,452
  • LY-341,495
  • MCPG
  • MGS-0039
  • PCCG-4; Negative allosteric modulators: Decoglurant
  • RO4491533
mGluR3Tooltip Metabotropic glutamate receptor 3
  • Agonists: CBiPES
  • DCG-IV
  • Eglumetad (LY-354740)
  • Glutamate
  • Ibotenic acid
  • LY-379,268
  • LY-487,379
  • MGS-0028
  • Pomaglumetad (LY-404039)
  • Pomaglumetad methionil (LY-2140023)
  • Talaglumetad (LY-544344)
  • Antagonists: APICA
  • CECXG
  • EGLU
  • HYDIA
  • LY-307,452
  • LY-341,495
  • MCPG
  • MGS-0039; Negative allosteric modulators: Decoglurant
  • RO4491533
Group III
mGluR4Tooltip Metabotropic glutamate receptor 4
  • Agonists: Glutamate
  • L-AP4
  • LSP2-9166
  • PHCCC
  • VU-001,171
  • VU-0155,041; Positive allosteric modulators: Foliglurax
  • MPEP
  • Antagonists: CPPG
  • MAP4
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
mGluR6Tooltip Metabotropic glutamate receptor 6
  • Agonists: Glutamate
  • L-AP4
  • Antagonists: CPPG
  • MAP4
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
mGluR7Tooltip Metabotropic glutamate receptor 7
  • Agonists: AMN082
  • Glutamate
  • L-AP4
  • LSP2-9166
  • Antagonists: CPPG
  • MAP4
  • MMPIP
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
  • XAP044; Negative allosteric modulators: ADX71743
mGluR8Tooltip Metabotropic glutamate receptor 8
  • Agonists: DCPG
  • Glutamate
  • L-AP4; Positive allosteric modulators: AZ12216052
  • Antagonists: CPPG
  • MAP4
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
See also: Receptor/signaling modulators • Ionotropic glutamate receptor modulators • Glutamate metabolism/transport modulators


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=ACPD&oldid=1330121067"
Categories:
  • Glutamic acids
  • MGlu1 receptor agonists
  • MGlu5 receptor agonists
  • NMDA receptor agonists
  • Cyclopentanes
  • Nervous system drug stubs
Hidden categories:
  • Chemical articles with multiple compound IDs
  • Multiple chemicals in an infobox that need indexing
  • Chemical articles with multiple CAS registry numbers
  • Chemical articles with multiple PubChem CIDs
  • Articles without InChI source
  • Articles without KEGG source
  • Articles without UNII source
  • Articles with changed CASNo identifier
  • Articles with changed EBI identifier
  • Articles with changed ChemSpider identifier
  • Articles with changed InChI identifier
  • Chembox having GHS data
  • Articles containing unverified chemical infoboxes
  • Articles with short description
  • Short description matches Wikidata
  • All articles with unsourced statements
  • Articles with unsourced statements from August 2017
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id